Scrip senior writer Joseph Haas overviews biopharma deal-making in 2022 and discusses the Pfizer/Seagen merger and what that may mean for pharma M&A during the remainder of 2023, with EF Hutton analyst Mike King and Mintz attorney Matt Gardella.
Want to check another podcast?
Enter the RSS feed of a podcast, and see all of their public statistics.
This website doesn't track the visitors or use any cookies. Made by Alex Barredo. Send your feedback to alex@barredo.es.